Literature DB >> 29176351

Bacteremia in Patients With Liver Cirrhosis: Prevalence and Predictors of Multidrug Resistant Organisms.

Jennifer N Addo Smith1, Raymond Yau1, Hannah P Russo1, Kimberly Putney1, Alejandro Restrepo2, Kevin W Garey3, Amelia K Sofjan3.   

Abstract

GOALS: The objective of this study was to assess the prevalence and predictors of multidrug resistant organisms (MDRO) in cirrhotic patients with bacteremia at a large tertiary center in the United States.
BACKGROUND: The epidemiology of bacteremia in patients with liver cirrhosis has not been well studied in the United States. STUDY: This case-case control study included 180 adults with liver cirrhosis hospitalized from 2011 to 2015. Case group 1 were patients with bacteremia due to a MDRO (n=30). Case group 2 were patients with bacteremia due to a non-MDRO (n=60). Control group comprised patients without bacteremia (n=90). MDRO was defined as bacteria that was nonsusceptible to ≥1 agent in ≥3 antimicrobial categories.
RESULTS: Of the 90 bacteremia episodes, 44% were because of gram-positive bacteria, 50% were because of gram-negative bacteria, and 6% were polymicrobial. MDROs caused 30 of 90 (33%) bacteremia episodes, including methicillin-resistant Staphylococcus species [12% (11/90)], fluoroquinolone-resistant Enterobacteriaceae [10% (9/90)], and Enterococcus faecium [3% (3/90)]. Eight percent of Enterobacteriaceae produced extended-spectrum β-lactamases. Four independent predictors of MDROs were identified: nonwhite race [adjusted odds ratio (aOR), 3.35; 95% confidence interval (CI), 1.19-9.38], biliary cirrhosis (aOR, 11.75; 95% CI, 2.08-66.32), blood cultures obtained >48 hours after hospital admission (aOR, 6.02; 95% CI, 1.70-21.40), and recent health care exposure (aOR, 9.81; 95% CI, 2.15-44.88).
CONCLUSIONS: A significant proportion of bacteremia in cirrhotic patients was due to MDROs at a large US tertiary care center. Local epidemiology data and identification of risk factors associated with MDROs may help with optimal empiric antibiotic selection.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29176351     DOI: 10.1097/MCG.0000000000000964

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

1.  Multi-drug resistant bacteria predict mortality in bloodstream infection in a tertiary setting in Tanzania.

Authors:  Joel Manyahi; Upendo Kibwana; Edna Mgimba; Mtebe Majigo
Journal:  PLoS One       Date:  2020-03-04       Impact factor: 3.240

2.  Treatment outcomes in patients with pyogenic vertebral osteomyelitis who have cirrhosis.

Authors:  Jihye Kim; Ho Suk Kang; Jeoung Woo Kim; Seok Woo Kim; Jae-Keun Oh; Young-Woo Kim; Moon Soo Park; Tae-Hwan Kim
Journal:  Sci Rep       Date:  2019-10-23       Impact factor: 4.379

Review 3.  Vaccination in Chronic Liver Disease: An Update.

Authors:  Joseph J Alukal; Haider A Naqvi; Paul J Thuluvath
Journal:  J Clin Exp Hepatol       Date:  2021-12-08

4.  Afebrile Bacteremia in Adult Emergency Department Patients with Liver Cirrhosis: Clinical Characteristics and Outcomes.

Authors:  Hung-Yu Chen; Yin-Chou Hsu
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

Review 5.  Variable Normalization of Naïve CD4+ Lymphopenia and Markers of Monocyte and T Cell Activation over the Course of Direct-Acting Anti-Viral Treatment of Chronic Hepatitis C Virus Infection.

Authors:  Ann W N Auma; Carey L Shive; Lenche Kostadinova; Donald D Anthony
Journal:  Viruses       Date:  2021-12-29       Impact factor: 5.048

6.  Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study.

Authors:  Elizabeth E Powell; Patricia C Valery; Amy L Johnson; Isanka U Ratnasekera; Katharine M Irvine; Andrew Henderson
Journal:  BMJ Open Gastroenterol       Date:  2021-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.